

# Chang Gong

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/103304/publications.pdf>

Version: 2024-02-01

47  
papers

2,376  
citations

361413  
20  
h-index

302126  
39  
g-index

47  
all docs

47  
docs citations

47  
times ranked

4267  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Cytoplasmic NF- $\kappa$ B Interacting Long Noncoding RNA Blocks $\kappa$ B Phosphorylation and Suppresses Breast Cancer Metastasis. <i>Cancer Cell</i> , 2015, 27, 370-381.	16.8	794
2	Circular RNA hsa_circ_001783 regulates breast cancer progression via sponging miR-200c-3p. <i>Cell Death and Disease</i> , 2019, 10, 55.	6.3	215
3	MicroRNAs and cancer: Key paradigms in molecular therapy (Review). <i>Oncology Letters</i> , 2017, 15, 2735-2742.	1.8	168
4	Autophagy-associated circRNA circCDYL augments autophagy and promotes breast cancer progression. <i>Molecular Cancer</i> , 2020, 19, 65.	19.2	143
5	Pretreatment neutrophil-to-lymphocyte ratio is correlated with response to neoadjuvant chemotherapy as an independent prognostic indicator in breast cancer patients: a retrospective study. <i>BMC Cancer</i> , 2016, 16, 320.	2.6	115
6	BRMS1L suppresses breast cancer metastasis by inducing epigenetic silence of FZD10. <i>Nature Communications</i> , 2014, 5, 5406.	12.8	84
7	NBAT1 suppresses breast cancer metastasis by regulating DKK1 via PRC2. <i>Oncotarget</i> , 2015, 6, 32410-32425.	1.8	80
8	The Rab2A GTPase Promotes Breast Cancer Stem Cells and Tumorigenesis via Erk Signaling Activation. <i>Cell Reports</i> , 2015, 11, 111-124.	6.4	80
9	HIF1 $\alpha$ -associated circDENND4C Promotes Proliferation of Breast Cancer Cells in Hypoxic Environment. <i>Anticancer Research</i> , 2017, 37, 4337-4343.	1.1	77
10	Prolyl Isomerase Pin1 Acts Downstream of miR200c to Promote Cancer Stem-like Cell Traits in Breast Cancer. <i>Cancer Research</i> , 2014, 74, 3603-3616.	0.9	68
11	E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter. <i>Oncotarget</i> , 2015, 6, 31944-31957.	1.8	62
12	Markers of Tumor-Initiating Cells Predict Chemoresistance in Breast Cancer. <i>PLoS ONE</i> , 2010, 5, e15630.	2.5	60
13	MiRNAs and Cancer: Key Link in Diagnosis and Therapy. <i>Genes</i> , 2021, 12, 1289.	2.4	44
14	Prognostic Value of a BCSC-associated MicroRNA Signature in Hormone Receptor-Positive HER2-Negative Breast Cancer. <i>EBioMedicine</i> , 2016, 11, 199-209.	6.1	43
15	Estrogen receptor beta as a prognostic factor in breast cancer patients: A systematic review and meta-analysis. <i>Oncotarget</i> , 2016, 7, 10373-10385.	1.8	37
16	The IRENA lncRNA converts chemotherapy-polarized tumor-suppressing macrophages to tumor-promoting phenotypes in breast cancer. <i>Nature Cancer</i> , 2021, 2, 457-473.	13.2	31
17	Distinct Receptor Tyrosine Kinase Subsets Mediate Anti-HER2 Drug Resistance in Breast Cancer. <i>Journal of Biological Chemistry</i> , 2017, 292, 748-759.	3.4	28
18	circCDYL2 promotes trastuzumab resistance via sustaining HER2 downstream signaling in breast cancer. <i>Molecular Cancer</i> , 2022, 21, 8.	19.2	28

#	ARTICLE	IF	CITATIONS
19	A Double-blind Randomized Controlled Trial of Toremifen Therapy for Mastalgia. Archives of Surgery, 2006, 141, 43.	2.2	25
20	Synthetic lethality between HER2 and transaldolase in intrinsically resistant HER2-positive breast cancers. Nature Communications, 2018, 9, 4274.	12.8	25
21	Effect of younger age on survival outcomes in T1N0M0 breast cancer: A propensity score matching analysis. Journal of Surgical Oncology, 2019, 119, 1039-1046.	1.7	22
22	Incorporating MicroRNA into Molecular Phenotypes of Circulating Tumor Cells Enhances the Prognostic Accuracy for Patients with Metastatic Breast Cancer. Oncologist, 2019, 24, e1044-e1054.	3.7	20
23	A new nomogram for predicting the malignant diagnosis of Breast Imaging Reporting and Data System (BI-RADS) ultrasonography category 4A lesions in women with dense breast tissue in the diagnostic setting. Quantitative Imaging in Medicine and Surgery, 2021, 11, 3005-3017.	2.0	17
24	Preoperative CA 15-3 levels predict the prognosis of nonmetastatic luminal A breast cancer. Journal of Surgical Research, 2014, 189, 48-56.	1.6	13
25	Silencing CTNND1 Mediates Triple-Negative Breast Cancer Bone Metastasis via Upregulating CXCR4/CXCL12 Axis and Neutrophils Infiltration in Bone. Cancers, 2021, 13, 5703.	3.7	13
26	A combination of Nottingham prognostic index and IHC4 score predicts pathological complete response of neoadjuvant chemotherapy in estrogen receptor positive breast cancer. Oncotarget, 2016, 7, 87312-87322.	1.8	12
27	Pretreatment DCE-MRI-Based Deep Learning Outperforms Radiomics Analysis in Predicting Pathologic Complete Response to Neoadjuvant Chemotherapy in Breast Cancer. Frontiers in Oncology, 2022, 12, 846775.	2.8	12
28	Hey Factors at the Crossroad of Tumorigenesis and Clinical Therapeutic Modulation of Hey for Anticancer Treatment. Molecular Cancer Therapeutics, 2017, 16, 775-786.	4.1	11
29	High-efficient Screening Method for Identification of Key Genes in Breast Cancer Through Microarray and Bioinformatics. Anticancer Research, 2017, 37, 4329-4335.	1.1	11
30	MiR-92b-3p Inhibits Proliferation of HER2-Positive Breast Cancer Cell by Targeting circCDYL. Frontiers in Cell and Developmental Biology, 2021, 9, 707049.	3.7	9
31	A 10-miRNA risk score-based prediction model for pathological complete response to neoadjuvant chemotherapy in hormone receptor-positive breast cancer. Science China Life Sciences, 2022, 65, 2205-2217.	4.9	7
32	Prognostic and predictive value of the combination of TOP2A and HER2 in node-negative tumors 2 cm or smaller (T1N0) breast cancer. Breast Cancer, 2020, 27, 1147-1157.	2.9	6
33	Non-coding RNAs as new autophagy regulators in cancer progression. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2022, 1868, 166293.	3.8	6
34	&lt;p&gt;The Effect of Low and High Vacuum Drainage on the Postoperative Drainage of Breast Cancer: Insights from a Prospective, Non-Inferiority, Randomized Clinical Trial&lt;/p&gt;. Cancer Management and Research, 2020, Volume 12, 12487-12496.	1.9	3
35	Specimen number based diagnostic yields of suspicious axillary lymph nodes in core biopsy in breast cancer: clinical implications from a prospective exploratory study. Quantitative Imaging in Medicine and Surgery, 2021, 11, 2151-2161.	2.0	2
36	Key Factors in Breast Cancer Dissemination and Establishment at the Bone: Past, Present and Future Perspectives. Advances in Experimental Medicine and Biology, 2017, 1026, 197-216.	1.6	1

#	ARTICLE	IF	CITATIONS
37	Anti-PITPNM3 small molecular compounds reverse breast cancer metastasis by targeting PITPNM3.. Journal of Clinical Oncology, 2021, 39, e15005-e15005.	1.6	1
38	Attenuation of PITPNM1 Signaling Cascade Can Inhibit Breast Cancer Progression. Biomolecules, 2021, 11, 1265.	4.0	1
39	The ratio of PD1+CD8+T cells in stromal area of tumor tissue is associated with the effect of neoadjuvant chemotherapy in HER2 negative breast cancer patients.. Journal of Clinical Oncology, 2022, 40, e12626-e12626.	1.6	1
40	Differences in tumor microenvironment between HER2-positive and HER2-negative breast cancer.. Journal of Clinical Oncology, 2022, 40, e12562-e12562.	1.6	1
41	BRMS1L inhibits bone metastasis of breast cancer cells through epigenetic silence of CXCR4.. Journal of Clinical Oncology, 2021, 39, e13002-e13002.	1.6	0
42	Ultrasound-Guided Vacuum-assisted Biopsy Versus Surgical Resection in Patients With Breast Desmoid Tumor. Journal of Surgical Research, 2021, 261, 400-406.	1.6	0
43	CTNND1 to mediate bone metastasis of triple-negative breast cancer via regulating CXCR4.. Journal of Clinical Oncology, 2021, 39, e13045-e13045.	1.6	0
44	Prognostic value of a BCSC-associated microRNA signature in hormone receptor-positive HER2-negative breast cancer.. Journal of Clinical Oncology, 2016, 34, 532-532.	1.6	0
45	A prognostic 10-miRNA risk score (10-miRNA RS) in predicting neoadjuvant chemotherapy sensitivity of luminal breast cancer.. Journal of Clinical Oncology, 2019, 37, 3139-3139.	1.6	0
46	Predictive value of circulating tumor cells <i>FTH1</i> gene on the efficacy of neoadjuvant chemotherapy in non-metastatic breast cancer.. Journal of Clinical Oncology, 2022, 40, e12599-e12599.	1.6	0
47	Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-lowâ€‘expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.. Journal of Clinical Oncology, 2022, 40, TPS620-TPS620.	1.6	0